Partnered Programs

Collaboration with Neurocrine Biosciences

In December 2019, we announced a license and collaboration agreement with Neurocrine Biosciences to develop treatments for epilepsy. The agreement includes exclusive licenses to Nav1.6 inhibitors and Nav1.2/1.6 inhibitors.

Neurocrine Biosciences is now focusing its efforts on progressing a Nav1.2/1.6 inhibitor towards human clinical trials in 2025 as a potential treatment for epilepsy.

For more information, please visit Neurocrine Biosciences.